Niitsu Nozomi, Nakamine Hirokazu, Okamoto Masataka, Akamatsu Hiroko, Higashihara Masaaki, Honma Yoshio, Okabe-Kado Junko, Hirano Masami
Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan.
Clin Cancer Res. 2004 Apr 1;10(7):2482-90. doi: 10.1158/1078-0432.ccr-03-0085.
Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin's lymphoma.
We used immunohistochemistry to examine the expression of nm23-H1 by the lymphoma cells in patients with diffuse large B-cell lymphoma (DLBCL).
By analyzing a consecutive series of 172 untreated DLBCL patients, we found that 100 (58.1%) were strongly positive. The cytoplasmic nm23 expression in lymphoma cells correlated significantly with the serum nm23-H1 level. There was a significant correlation between patients with cytoplasmic nm23-positive lymphoma and those with performance status 2-4, stage III/IV, bulky mass, B symptoms, elevated serum level of soluble interleukin 2 receptor, and elevated serum level of C-reactive protein. Overall and progression-free survival rates were significantly lower in patients with nm23-H1-positive lymphomas than in those with nm23-H1-negative lymphomas. Similar difference was seen between patients with high and low serum levels of nm23-H1. Thus, the correlation between presence or absence of cytoplasmic nm23-H1 expression and serum nm23-H1 levels suggests that serum nm23-H1 is produced directly by lymphoma cells.
We suggest that nm23-H1 expression is a prognostic factor for DLBCL, and that it is as important as serum nm23-H1, both of which are useful for planning a treatment strategy.
最近，我们建立了一种用于检测血清中nm23-H1蛋白的ELISA技术，并发现血清nm23-H1水平是非霍奇金淋巴瘤患者的一个潜在预后因素。
我们采用免疫组织化学方法检测弥漫性大B细胞淋巴瘤（DLBCL）患者淋巴瘤细胞中nm23-H1的表达。
通过分析连续的172例未经治疗的DLBCL患者，我们发现100例（58.1%）呈强阳性。淋巴瘤细胞中的细胞质nm23表达与血清nm23-H1水平显著相关。细胞质nm23阳性淋巴瘤患者与体能状态为2-4、III/IV期、大包块、B症状、可溶性白细胞介素2受体血清水平升高和C反应蛋白血清水平升高的患者之间存在显著相关性。nm23-H1阳性淋巴瘤患者的总生存率和无进展生存率显著低于nm23-H1阴性淋巴瘤患者。血清nm23-H1水平高和低的患者之间也有类似差异。因此，细胞质nm23-H1表达的有无与血清nm23-H1水平之间的相关性表明血清nm23-H1是由淋巴瘤细胞直接产生的。
我们认为nm23-H1表达是DLBCL的一个预后因素，并且它与血清nm23-H1同样重要，二者都有助于制定治疗策略。
